Automate Your Wheel Strategy on NAMSW
With Tiblio's Option Bot, you can configure your own wheel strategy including NAMSW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAMSW
- Rev/Share 0.5689
- Book/Share 6.9194
- PB 3.3869
- Debt/Equity 0.0004
- CurrentRatio 21.0848
- ROIC -0.2219
- MktCap 2639437180.0
- FreeCF/Share -1.1048
- PFCF -21.2337
- PE -15.9109
- Debt/Assets 0.0004
- DivYield 0
- ROE -0.2462
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About NewAmsterdam Pharma Company N.V. (NAMSW)
- IPO Date 2021-02-10
- Website https://www.newamsterdampharma.com
- Industry Biotechnology
- CEO Michael Harvey Davidson FACC, Facp.,
- Employees 68
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.